AEMDHealthcare · Medical DevicesThe 2 Wall Street analysts covering Aethlon Medical, Inc. hold a median 12-month price target of $13 — +120.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Aethlon Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AEMD, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +120.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | $1.50 |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 7 July 2025 | HC Wainwright & Co. | Assumes | Neutral | $1.50 |
| 10 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2022 | Maxim Group | Downgrade | Hold | — |
| 25 June 2021 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $9.00 |
| 1 June 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 8 Jan 2021 | Maxim Group | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AEMD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 83% of US stocks
Cheaper than 61% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aethlon Medical, Inc. has a market value of $9.6M and an enterprise value of −$249K.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$7.2M.
Free cash flow in the twelve months to 31 Mar 2026: −$7.0M.
Trailing P/E: 0.0×; forward P/E: −10.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aethlon Medical, Inc. employs 9 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aethlon Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A transcript of prepared remarks from an Aethlon Medical, Inc. shareholder/analyst call was published by Seeking Alpha, capturing the company's official commentary from the event.
Why it matters — AEMD watchers would refer to the transcript to review the company's own statements and updates from its shareholder/analyst call.
Aethlon Medical Inc. shares fell on Friday, pulling back after surging more than 300% the previous day. The decline reflects a reversal of the prior session's sharp move higher.
Why it matters — AEMD watchers would care because the pullback follows an unusually large price surge, indicating significant volatility in the stock's recent trading.
Brodsky & Smith issued a shareholder update reminding investors of ongoing investigations involving several companies, including Aethlon Medical (Nasdaq – AEMD), along with Ruger, Atkore, and Centerspace. The firm invited shareholders to discuss the investigations at no cost or financial obligation.
Why it matters — The notice alerts AEMD watchers that the company has been named in a law firm's shareholder investigation, which could draw attention to potential issues with the stock.
Aethlon Medical announced an all-stock merger agreement with privately held biotech firm North Immunology Inc., signaling a pivot to biotechnology. Following the announcement, the company's stock rose sharply on Thursday.
Why it matters — AEMD watchers would care because the merger marks a strategic shift in the company's business direction toward biotechnology.
Investor rights law firm Halper Sadeh LLC announced it is investigating whether Aethlon Medical, Inc. is obtaining a fair price for its shareholders in the proposed merger with North Immunology, Inc. Under the deal terms, Aethlon shareholders are expected to own approximately 4.75% of the combined company upon closing.
Why it matters — AEMD shareholders may face scrutiny of the merger's fairness and terms, which could affect the value they receive from the proposed transaction.
The 2 Wall Street analysts covering Aethlon Medical, Inc. have a median 12-month price target of $13, with estimates ranging from $1.5 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Aethlon Medical, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aethlon Medical, Inc. 26 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Aethlon Medical, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +120.5% from the last close, and Ticker Nerd's factor model ranks Aethlon Medical, Inc. 26 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aethlon Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $25 over the next 12 months.
Aethlon Medical, Inc. is a medical therapeutic company focused on developing immunotherapeutic technologies for oncology and infectious disease.
The most recent item we track (Seeking Alpha, 1 Oct 2026): "Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript". A transcript of prepared remarks from an Aethlon Medical, Inc. shareholder/analyst call was published by Seeking Alpha, capturing the company's official commentary from the event.
Aethlon Medical, Inc. is a medical therapeutic company focused on developing immunotherapeutic technologies for oncology and infectious disease. Its lead product, the Hemopurifier, is a clinical-stage extracorporeal device designed to remove circulating disease-related targets from blood and other biologic fluids. The company’s work spans applications in cancer care, life-threatening viral infections, and organ transplantation, with a broader emphasis on addressing unmet needs in medical treatment and biodefense. Aethlon Medical combines device-based therapy and filtration science to support clinical research in areas where current options remain limited. Headquartered in San Diego, California, the company operates as a specialized player in the healthcare sector, concentrating on advanced therapeutic devices rather than broad pharmaceutical products.
CEO Mr. James B. Frakes M.B.A. · 9 employees · United States · https://www.aethlonmedical.com